2,3-dihydro-6,7,4'-trihydroxyisoflavone | 94105-87-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 2,3-dihydro-6,7,4'-trihydroxyisoflavone
• 英文别名: 4',6,7-trihydroxyisoflavanone；6,7-dihydroxy-3-(4-hydroxy-phenyl)-chroman-4-one；6,7,4'-trihydroxydihydroisoflavone；6-Hydroxydihydrodaidzein；6,7-dihydroxy-3-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
• CAS: 94105-87-0
• 化学式: C₁₅H₁₂O₅
• 分子量: 272.257
• InChiKey: ZAIJTQZQMCNJHG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4’,6,7-三羟异黄酮 在 palladium on activated charcoal 氢气 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 6.0h， 以48%的产率得到2,3-dihydro-6,7,4'-trihydroxyisoflavone
  参考文献：
  名称：

  Structure–activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2

  摘要：

  Human lipoxygenase (hLO) isozymes have been implicated in a number of disease states and have attracted much attention with respect to their inhibition. One class of inhibitors, the flavonoids, have been shown to be potent lipoxygenase inhibitors but their study has been restricted to those compounds found in nature, which have limited structural variability. We have therefore carried out a comprehensive study to determine the structural requirements for flavonoid potency and selectivity against platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2. We conclude from this study that catechols are essential for high potency, that isoflavones and isoflavanones tend to select against 12-hLO, that isoflavans tend to select against 15-hLO-1, but few flavonoids target 15-hLO-2. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.07.036

文献信息

• Nitric oxide donating derivatives for the treatment of cardiovascular disorders
  申请人：Tucker Joseph

  公开号：US20050080024A1

  公开（公告）日：2005-04-14

  Compounds comprising nitric oxide derivatives of stilbenes, polyphenols and flavonoids and methods of their use are provided for treating patients suffering from any of hypercholesterolemia, vascular oxidative stress and endothelial dysfunction.

  本发明提供了由stilbenes、多酚和类黄酮的亚硝酸盐衍生物组成的化合物，以及它们的使用方法，用于治疗患有高胆固醇血症、血管氧化应激和内皮功能障碍的患者。
• Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
  申请人：Tucker Joseph

  公开号：US20050080021A1

  公开（公告）日：2005-04-14

  Compounds and methods are provided for treating patients suffering from any of hypercholesterolemia, vascular oxidative stress and endothelial dysfunction.

  提供了用于治疗患有高胆固醇血症、血管氧化应激和内皮功能障碍的患者的化合物和方法。
• Isoflavone metabolites
  申请人：Joannou Eustace George

  公开号：US20050222248A1

  公开（公告）日：2005-10-06

  There are disclosed compounds of formulae (I) or (II) in which A is selected from the group consisting of (1), (2), (3) and (4);OH, and one of R 1 and R 2 is selected from H, OH and OCH 3 , and the other of R 1 and R 2 is selected from OH and OCH 3 ; one of R3 and R4 is selected from H, OH and OCH3, and the other of R3 and R4 is selected from OH and OCH3; provided that at least one of the pairs R 1 , R 2 and R 3 , R 4 are both OH; R 5 is selected from OH and OCH 3 ; and ------ denotes a single or double bond; and pharmaceutically acceptable salts and prodrugs thereof. The compounds of the invention are useful for the treatment of hormone-dependent conditions and cancers.

  在公式（I）或（II）中披露了化合物，其中A选自以下组合：（1）、（2）、（3）和（4）；OH，R1和R2中的一个选自H、OH和OCH3，另一个选自OH和OCH3；R3和R4中的一个选自H、OH和OCH3，另一个选自OH和OCH3；前提是R1、R2和R3、R4中至少有一对是OH；R5选自OH和OCH3；以及------表示单键或双键；以及其药学上可接受的盐和前药。该发明的化合物对于治疗激素依赖性疾病和癌症是有用的。
• ISOFLAVONE METABOLITES
  申请人：Joannou George Eustace

  公开号：US20080125481A1

  公开（公告）日：2008-05-29

  There are disclosed compounds of formulae (I) or (II) in which A is selected from the group consisting of (1), (2), (3) and (4); OH, and one of R 1 and R 2 is selected from H, OH and OCH 3 , and the other of R 1 and R 2 is selected from OH and OCH 3 ; one of R3 and R4 is selected from H, OH and OCH3, and the other of R3 and R4 is selected from OH and OCH3; provided that at least one of the pairs R 1 , R 2 and R 3 , R 4 are both OH; R 5 is selected from OH and OCH 3 ; and denotes a single or double bond; and pharmaceutically acceptable salts and prodrugs thereof. The compounds of the invention are useful for the treatment of hormone-dependent conditions and cancers.

  公开了式（I）或（II）的化合物，其中A从（1），（2），（3）和（4）组成的群体中选择；OH，R1和R2中的一个选择自H，OH和OCH3，另一个选择自OH和OCH3；R3和R4中的一个选择自H，OH和OCH3，另一个选择自OH和OCH3；前提是R1，R2和R3，R4中至少有一对是OH；R5选择自OH和OCH3；并表示单键或双键；以及其药学上可接受的盐和前药。本发明的化合物用于治疗激素依赖性疾病和癌症。
• Glycan therapeutics and related methods thereof
  申请人：KALEIDO BIOSCIENCES, INC.

  公开号：US10314853B2

  公开（公告）日：2019-06-11

  Preparations of glycan therapeutics, pharmaceutical compositions and medical foods thereof, optionally comprising micronutrients, polyphenols, prebiotics, probiotics, or other agents are provided and methods of making same. Also provided are methods of using said gycan therapeutics, e.g. for the modulation of human gastrointestinal microbiota and to treat dysbioses.

  本发明提供了可选择包含微量营养素、多酚、益生元、益生菌或其他制剂的聚糖疗法制剂、药物组合物及其医用食品，以及制造方法。还提供了使用所述糖治疗剂的方法，例如用于调节人类胃肠道微生物群和治疗菌群失调。